Reply to: Doherty T, Daly EJ, Miller J, Popova V, Cepeda MS, Drevets WC, et al. Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis. Psychother Psychosom. DOI: 10.1159/000512311. Referred to: Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety con-cerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Psy-chother Psychosom. DOI: 10.1159/000510703.
Reply to the Comments by Doherty et al
Gastaldon, Chiara
;Barbui, Corrado;
2021-01-01
Abstract
Reply to: Doherty T, Daly EJ, Miller J, Popova V, Cepeda MS, Drevets WC, et al. Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis. Psychother Psychosom. DOI: 10.1159/000512311. Referred to: Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety con-cerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Psy-chother Psychosom. DOI: 10.1159/000510703.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
